Burkitt lymphoma is a rare, highly aggressive B-cell non-hodgkin lymphoma. Burkitt lymphoma disease may affect jaw, central nervous system, bowel, kidneys, ovaries, or other organs. There are three main types of Burkitt lymphoma: endemic, sporadic, and immunodeficiency-related. Endemic Burkitt lymphoma is the most common of the three types, originating in Africa, where it is still the most common childhood cancer. Endemic Burkitt lymphoma is rare outside of Africa. Sporadic Burkitt lymphoma occurs throughout the world. The immunodeficiency-related variety of Burkitt lymphoma is most common in people with human immunodeficiency virus/acquired immunodeficiency syndrome. Translocation of the MYC gene is a hallmark of Burkitt lymphoma, making this an important finding for diagnosis of the disease, however, abnormalities in this gene are found in other aggressive mature B-cell lymphomas as well. The drug candidates in the pipeline of Burkitt lymphoma include, but are not limited to, Duvortuxizumab, AZD 3965 and UCART19.
Some of the companies having drugs in the Burkitt lymphoma pipeline include Arvinas, Inc., Bluebird bio, Inc., Constellation Pharmaceuticals, Inc. and Theravectys SA.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.